Coronary heart disease risk markers users low-dose oral contraceptives Seven combination oral contraceptives OCs effects glucose insulin triglyceride lipoprotein concentrations Subjects women fixed-dose monophasic variable-dose triphasic formulations premenopausal women OCs monophasics micrograms levonorgestrel micrograms norethindrone micrograms desogestrel progestin Triphasic progestin doses micrograms levonorgestrel micrograms norethindrone formulations fasting serum triglycerides changes serum total cholesterol effects serum lipoproteins progestin type dose Monophasics micrograms norethindrone micrograms desogestrel low density lipoprotein LDL cholesterol high density lipoprotein HDL cholesterol Monophasics levonorgestrel HDL cholesterol triphasics LDL HDL cholesterol balance HDL subfractions formulations deterioration glucose tolerance insulin resistance pancreatic insulin secretion effects formulations levonorgestrel study reduction progestin dose use novel progestins adverse effects OCs metabolic risk markers coronary heart disease 